Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 18, 23 | -0.31 Decreased by -19.23% | -0.23 Decreased by -151.23% |
| Apr 3, 23 | -0.18 Increased by +37.93% | -0.19 Increased by +27.70% |
| Mar 30, 23 | -0.18 Increased by +37.93% | -0.19 Increased by +27.70% |
| Nov 8, 22 | -0.23 Increased by +25.81% | -0.24 Increased by +17.36% |
| Aug 4, 22 | -0.26 Increased by +10.34% | -0.28 Increased by +25.51% |
| May 12, 22 | -0.29 Decreased by -31.82% | -0.30 Increased by +11.11% |
| Mar 23, 22 | -0.29 Decreased by -45.00% | -0.35 Increased by +48.98% |
| Nov 9, 21 | -0.31 Decreased by -29.17% | -0.31 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -21.81 M Decreased by -7.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 25.97 M Increased by +N/A% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -15.10 M Increased by +28.90% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -18.23 M Increased by +8.02% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -20.27 M Decreased by -42.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by -100.00% | 0.00 Increased by +100.00% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by -100.00% | -21.23 M Decreased by -87.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by -100.00% | -19.82 M Decreased by -58.34% | Decreased by N/A% Decreased by N/A% |
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.